analgesic action of Nise tablet

Nise tablet is a relatively COX-2 selective with analgesic and antipyretic properties. It's one of the brand for the Nimesulide medicine.

Nise is the best prescribed treatment for post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.

Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.

The prescription of a drug is appropriate when the benefit it is able to provide to a specific patient outweigh the risks associated with its use. A careful evaluation of individual risk factors is therefore of crucial importance.

It shows the rapid onset of analgesic action shows the immediate relief within the 15 min from the drug intake for the acute pain.

Nimesulide and its antipyretic properties

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. 

NImesulide shows multifactorial mode of action for the treatment of for post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.

The drug is developed by Helsinn Healthcare. Medicines containing Nimesulide are on the market since 1985 and are authorised in a number of Member States.

Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.

Nimesulide is available in the form of tablets (100 mg), granules for oral suspension (100 mg), suppositories (200 mg) and gel (3%).

The maximum duration and dose of a treatment course with Nimesulide is 15 days, 100 mg twice a day, to minimize the risk of hepatotoxicity.

Nimesulide Forms

Nimesulide has superior gastrointestinal safety as compared to other NSAIDs with multi factorial approach for treating post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness. It was launched in Italy for the first time as Aulin and Mesulid in 1985 and is presently available in more than 50 countries worldwide in different trademarks Its multifactorial mode of action gives it a unique and broad action on inflammatory processes. It is available in the market in various like tablets (100 mg), granules for oral suspension (100 mg), suppositories (200 mg) and gel (3%). The Gel needed to be applied is three to four times per day depending on the dimension of the affected size and response. Medicalcare ought to be reviewed after 4 weeks. Trademarks of NImesulide include of Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan e.t.c. Nimulid Transgel is indicated for post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.